We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Rapid Assay Predicts Response to Flu Vaccine

By LabMedica International staff writers
Posted on 21 Jul 2011
An assay predicts, within a few days, whether an individual will produce high levels of antibodies against an influenza vaccine.

Scientists scanned the extent to which selected genes are turned on in white blood cells and predicted, on day three, with up to 90% accuracy, who would make high levels of antibodies against a standard flu vaccine four weeks later. More...


The approach, which involved immunology, genomics, and bioinformatics, was pioneered by Bali Pulendran, PhD, professor of pathology and laboratory medicine at Emory University School of Medicine (Atlanta, GA, USA) and Yerkes National Primate Research Center (Atlanta, GA, USA) when studying the yellow fever vaccine. He worked with colleagues from the Georgia Institute of Technology (Atlanta, GA, USA), Duke University (Durham, NC, USA), Dana Farber Cancer Institute, Institute for Systems Biology (Boston, MA, USA) and the National Institute of Allergy and Infectious Diseases (Bethesda, MD, USA) to extend this approach to the influenza vaccine, against which many people have some preexisting immunity.

Prof. Pulendran was senior author of a paper reporting the results of the flu vaccine study that were published online on July 10, 2011, in the journal Nature Immunology.

The predictive model is based on a series of clinical studies during the annual flu seasons in 2007, 2008, and 2009. Healthy young adults were vaccinated with a standard flu shot (trivalent inactive vaccine). Others were given live attenuated vaccine nasally.

The activity levels of all human genes were surveyed in blood samples from the volunteers. The activity of many genes involved in innate immunity, interferon, and reactive oxygen species signaling changed after flu vaccination. The team also identified genes in the unfolded protein response, necessary for cells to adapt to the stress of producing high levels of antibodies.

A computer model was developed using the gene activity data from one season to identify small groups of genes that can predict high and low responders. Later, the scientists examined whether the model could forecast who would be high or low responders in two other flu seasons.

"The main goal of our study was to demonstrate the feasibility of predicting how strongly a vaccine will stimulate the immune system," said Prof. Pulendran "Along the way, we have developed an assay that focuses on a handful of genes, which could be the basis for a customized vaccine chip to make these predictions cost-effectively."

Related Links:
Emory University School of Medicine
Yerkes National Primate Research Center
National Institute of Allergy and Infectious Diseases


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.